Phase 2 Study of Erlotinib Versus Gefitinib in Advanced Non Small Cell Lung Cancer With exon21 Mutation.

Trial Profile

Phase 2 Study of Erlotinib Versus Gefitinib in Advanced Non Small Cell Lung Cancer With exon21 Mutation.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
    • 29 Jul 2013 Planned end date changed from 1 Jul 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 05 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top